彭布罗利珠单抗
浆液性卵巢癌
卵巢癌
佐剂
医学
浆液性液体
肿瘤科
阶段(地层学)
内科学
妇科
癌症
生物
免疫疗法
古生物学
作者
S. Lot Aronson,Bram Thijssen,Marta López‐Yurda,Simone N. Koole,Paul van der Leest,Alicia León‐Castillo,Rolf Harkes,Iris M. Seignette,Joyce Sanders,M. Alkemade,Inge Kemper,M. Holtkamp,Ingrid A.M. Mandjes,A. Broeks,Max J. Lahaye,Martin A. Rijlaarsdam,Diane van den Broek,Lodewyk F.A. Wessels,Hugo M. Horlings,Willemien J. van Driel
标识
DOI:10.1038/s41467-025-58440-y
摘要
While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, their efficacy in high-grade serous ovarian cancer (HGSOC) remains limited. Some patients, however, achieve lasting responses, emphasizing the need to understand how tumor microenvironment and molecular characteristics influence ICI response. The phase 2 Neo-Pembro study (NCT03126812) included 33 untreated stage IV HGSOC patients, who were scheduled for 6 cycles of carboplatin-paclitaxel and interval cytoreductive surgery. Pembrolizumab (pembro) was added from cycle two and continued for one year. The primary objective was to assess intratumoral immune activation using multiplexed immunofluorescence and immune-related gene expression. Our findings show immune activation, evidenced by an increase in CD3 + , CD8 + , CD8 + /FOXP3+ ratio, TNF-α and interferon-γ signaling. Treatment was well-tolerated. We observed major pathologic responses in 9/33 patients (27%, 95%CI 14-46), with pathologic response strongly associated with immune activation and OS. At a median follow-up of 52.8 months, 8/9 major responders were alive, with 6 patients recurrence-free. In contrast, 4/24 minor responders survived, including one recurrence-free. ctDNA clearance was observed in all major responders and was associated with prolonged PFS and OS. PD-L1 expression and homologous recombination deficiency were predictive of major response and may serve as biomarkers, warranting further exploration. These results suggest major responders may benefit from neo-adjuvant pembro.
科研通智能强力驱动
Strongly Powered by AbleSci AI